These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

414 related articles for article (PubMed ID: 27411517)

  • 1. SOX2 expression is associated with a cancer stem cell state and down-regulation of CDX2 in colorectal cancer.
    Lundberg IV; Edin S; Eklöf V; Öberg Å; Palmqvist R; Wikberg ML
    BMC Cancer; 2016 Jul; 16():471. PubMed ID: 27411517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer.
    Kim JH; Rhee YY; Bae JM; Cho NY; Kang GH
    Am J Surg Pathol; 2013 Oct; 37(10):1532-41. PubMed ID: 24025523
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible role of Cdx2 in the serrated pathway of colorectal cancer characterized by BRAF mutation, high-level CpG Island methylator phenotype and mismatch repair-deficiency.
    Dawson H; Galván JA; Helbling M; Muller DE; Karamitopoulou E; Koelzer VH; Economou M; Hammer C; Lugli A; Zlobec I
    Int J Cancer; 2014 May; 134(10):2342-51. PubMed ID: 24166180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation.
    Lee S; Cho NY; Choi M; Yoo EJ; Kim JH; Kang GH
    Pathol Int; 2008 Feb; 58(2):104-13. PubMed ID: 18199160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive analysis of CpG island methylator phenotype (CIMP)-high, -low, and -negative colorectal cancers based on protein marker expression and molecular features.
    Zlobec I; Bihl M; Foerster A; Rufle A; Lugli A
    J Pathol; 2011 Nov; 225(3):336-43. PubMed ID: 21660972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SOX2 expression is regulated by BRAF and contributes to poor patient prognosis in colorectal cancer.
    Lundberg IV; Löfgren Burström A; Edin S; Eklöf V; Öberg Å; Stenling R; Palmqvist R; Wikberg ML
    PLoS One; 2014; 9(7):e101957. PubMed ID: 25010701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer.
    Bruun J; Sveen A; Barros R; Eide PW; Eilertsen I; Kolberg M; Pellinen T; David L; Svindland A; Kallioniemi O; Guren MG; Nesbakken A; Almeida R; Lothe RA
    Mol Oncol; 2018 Sep; 12(9):1639-1655. PubMed ID: 29900672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loss of CDX2 expression is associated with poor prognosis in colorectal cancer patients.
    Bae JM; Lee TH; Cho NY; Kim TY; Kang GH
    World J Gastroenterol; 2015 Feb; 21(5):1457-67. PubMed ID: 25663765
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic significance of MUC2, CDX2 and SOX2 in stage II colorectal cancer patients.
    Ribeirinho-Soares S; Pádua D; Amaral AL; Valentini E; Azevedo D; Marques C; Barros R; Macedo F; Mesquita P; Almeida R
    BMC Cancer; 2021 Apr; 21(1):359. PubMed ID: 33823840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship of CDX2 loss with molecular features and prognosis in colorectal cancer.
    Baba Y; Nosho K; Shima K; Freed E; Irahara N; Philips J; Meyerhardt JA; Hornick JL; Shivdasani RA; Fuchs CS; Ogino S
    Clin Cancer Res; 2009 Jul; 15(14):4665-73. PubMed ID: 19584150
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis.
    Zlobec I; Bihl MP; Schwarb H; Terracciano L; Lugli A
    Int J Cancer; 2010 Jul; 127(2):367-80. PubMed ID: 19908233
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive clinicopathologic, molecular, and immunologic characterization of colorectal carcinomas with loss of three intestinal markers, CDX2, SATB2, and KRT20.
    Lee JA; Seo MK; Yoo SY; Cho NY; Kwak Y; Lee K; Kim JH; Kang GH
    Virchows Arch; 2022 Mar; 480(3):543-555. PubMed ID: 35029777
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRAF-mutated microsatellite stable colorectal carcinoma: an aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression.
    Landau MS; Kuan SF; Chiosea S; Pai RK
    Hum Pathol; 2014 Aug; 45(8):1704-12. PubMed ID: 24908142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CDX2 in colorectal cancer is an independent prognostic factor and regulated by promoter methylation and histone deacetylation in tumors of the serrated pathway.
    Graule J; Uth K; Fischer E; Centeno I; Galván JA; Eichmann M; Rau TT; Langer R; Dawson H; Nitsche U; Traeger P; Berger MD; Schnüriger B; Hädrich M; Studer P; Inderbitzin D; Lugli A; Tschan MP; Zlobec I
    Clin Epigenetics; 2018 Sep; 10(1):120. PubMed ID: 30257705
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of p21 (CDKN1A/CIP1) is inversely associated with microsatellite instability and CpG island methylator phenotype (CIMP) in colorectal cancer.
    Ogino S; Kawasaki T; Kirkner GJ; Ogawa A; Dorfman I; Loda M; Fuchs CS
    J Pathol; 2006 Oct; 210(2):147-54. PubMed ID: 16850502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of Caudal-Type Homeobox Transcription Factor 2 Expression as a Prognostic Biomarker in Metastatic Colorectal Cancer.
    Zhang BY; Jones JC; Briggler AM; Hubbard JM; Kipp BR; Sargent DJ; Dixon JG; Grothey A
    Clin Colorectal Cancer; 2017 Jun; 16(2):124-128. PubMed ID: 27726953
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The prognostic impact of CDX2 correlates with the underlying mismatch repair status and BRAF mutational status but not with distant metastasis in colorectal cancer.
    Neumann J; Heinemann V; Engel J; Kirchner T; Stintzing S
    Virchows Arch; 2018 Aug; 473(2):199-207. PubMed ID: 29675807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CDX2 Protein Expression in Colorectal Cancer and ItsCorrelation with Clinical and Pathological Characteristics, Prognosis, and Survival Rate of Patients.
    Asgari-Karchekani S; Karimian M; Mazoochi T; Taheri MA; Khamehchian T
    J Gastrointest Cancer; 2020 Sep; 51(3):844-849. PubMed ID: 31630373
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sidedness Matters: Surrogate Biomarkers Prognosticate Colorectal Cancer upon Anatomic Location.
    Ben-Aharon I; Goshen-Lago T; Sternschuss M; Morgenstern S; Geva R; Beny A; Dror Y; Steiner M; Hubert A; Idelevich E; Shulman K; Mishaeli M; Man S; Liebermann N; Soussan-Gutman L; Brenner B
    Oncologist; 2019 Aug; 24(8):e696-e701. PubMed ID: 30755502
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status.
    Dahlin AM; Palmqvist R; Henriksson ML; Jacobsson M; Eklöf V; Rutegård J; Oberg A; Van Guelpen BR
    Clin Cancer Res; 2010 Mar; 16(6):1845-55. PubMed ID: 20197478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.